Easywell Biomedicals, Inc. (TPEX:1799)

Market Cap	4.15B -46.2%
Revenue (ttm)	682.56M +10.3%
Net Income	-52.13M
EPS	-0.42
Shares Out	124.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123,381
Open	33.20
Previous Close	33.20
Day's Range	33.10 - 33.65
52-Week Range	27.65 - 61.60
Beta	-0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-017 for the treatment of chronic angina; and TLX-011 for the treatment o...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1799

Financial Performance

In 2025, Easywell Biomedicals's revenue was 597.41 million, an increase of 10.54% compared to the previous year's 540.44 million. Losses were -73.14 million, -24.96% less than in 2024.